Most peptides swallowed as a pill or liquid are destroyed before they reach the bloodstream, broken apart by stomach acid and digestive enzymes and then blocked by the intestinal lining itself. That said, oral peptide delivery is not impossible. One peptide drug, semaglutide (sold as Rybelsus), is already prescribed as a daily tablet for type 2 diabetes and works well enough to have changed the field’s assumptions about what oral peptides can do. The science behind getting peptides past the gut involves a gauntlet of biological barriers and an increasingly creative set of engineering solutions to overcome them.
Why the Gut Destroys Most Peptides
Your digestive system evolved specifically to break proteins and peptides into their component amino acids so you can absorb and reuse them. That is exactly the wrong environment for a peptide drug that needs to arrive intact at its target. The destruction starts in the stomach, where hydrochloric acid and the enzyme pepsin begin chopping peptide bonds, particularly at sites near certain amino acids. But the stomach is only the opening act. The small intestine is where the real damage happens: a battery of pancreatic enzymes including trypsin, chymotrypsin, elastase, and carboxypeptidases covers a wide range of cleavage targets, meaning almost no unmodified peptide sequence escapes uncut. On top of that, enzymes anchored directly to the intestinal lining (brush border peptidases) finish off fragments that survived the earlier rounds.
1ACS Publications (Journal of Medicinal Chemistry). On the Utility of Chemical Strategies to Improve Peptide Gut StabilityEven if a peptide somehow dodges all those enzymes, the intestinal wall itself is a formidable barrier. The epithelium is a single layer of tightly packed cells connected by structures called tight junctions, which seal the gaps between cells and prevent large molecules from leaking through. A typical peptide drug is too big and too water-soluble to slip across cell membranes on its own, and too large to pass through the narrow paracellular spaces between cells. The combination of enzymatic destruction and poor membrane penetration is the core reason oral bioavailability of most peptide drugs is extremely low.
2PubMed. Oral delivery of peptide drugs: barriers and developmentsHow Small Peptides Naturally Get Absorbed
The gut is not completely closed to peptides. Your body has a built-in transporter called PepT1, located on the surface of intestinal cells, whose entire job is to pull small peptides (two or three amino acids long) from the intestinal lumen into the cell. PepT1 is remarkably versatile: it can transport essentially every possible combination of two or three amino acids, using a proton gradient as its energy source.
3PubMed. Molecular and integrative physiology of intestinal peptide transportThis transporter is the reason your body efficiently absorbs protein from food. Digestive enzymes break dietary protein down to di- and tripeptides, and PepT1 ferries them across the intestinal wall. It also explains why certain small-molecule drugs designed to mimic dipeptides (like some antibiotics) can be absorbed orally by hitchhiking on PepT1.
4PubMed Central. Clinical relevance of intestinal peptide uptakeThe catch is that most therapeutic peptides are far larger than two or three amino acids. Insulin, for instance, is 51 amino acids. Semaglutide is 31. These molecules are too big for PepT1, so they cannot use this natural shortcut. For larger peptides, researchers have had to find other ways in.
The Liver Adds Another Hurdle
Even the fraction of a peptide that does cross the intestinal wall is not home free. Blood draining from the intestines flows directly to the liver through the portal vein before reaching the general circulation. The liver is packed with enzymes that break down foreign molecules, and peptides are no exception. In perfusion studies using rat liver, roughly 30 to 35 percent of one model peptide (metkephamid) was destroyed during this single pass through the liver. Other peptides fared better: the hormone-releasing factor TRH lost less than 10 percent to hepatic metabolism.
5PubMed. First-pass metabolism of peptide drugs in rat perfused liverHow much a peptide loses in the liver depends on its structure, but the point is that first-pass metabolism is yet another layer of attrition on top of enzymatic digestion and poor gut absorption. By the time you add up all three barriers, it becomes clear why most injected peptide drugs cannot simply be reformulated as pills without sophisticated delivery technology.
Oral Semaglutide and the SNAC Breakthrough
The most prominent success story in oral peptide delivery is semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight management. The oral tablet (Rybelsus) pairs semaglutide with a small molecule called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which acts as a permeation enhancer. SNAC does several things at once in the stomach: it locally raises pH around the tablet, which inhibits the digestive enzyme pepsin and protects the peptide from degradation. It also promotes absorption of semaglutide across the stomach lining through a transcellular route, meaning the peptide passes through stomach cells rather than between them, without disrupting tight junctions.
6PubMed. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonistInterestingly, semaglutide absorption happens in the stomach rather than in the intestine, which is the opposite of what happens with most small-molecule drugs. Clinical and animal studies confirmed that the absorption is confined to the area immediately around the dissolving tablet surface and requires SNAC to be physically present alongside the peptide.
6PubMed. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonistHow SNAC enhances permeation at a molecular level is still being refined. Solid-state NMR research has shown that SNAC increases the fluidity of cell membranes in a concentration-dependent way, boosting fluidity at the hydrophobic center of lipid membranes by about 43 percent at higher concentrations. At the same time, adding a peptide drug into the mix creates a competitive interaction between the enhancer, the membrane lipids, and the peptide, making the system more complex than a simple “open the door” model.
7PubMed. Molecular Investigation of SNAC as an Oral Peptide Permeation Enhancer in Lipid Membranes via Solid-State NMRWhy Oral Semaglutide Has Such Strict Dosing Rules
If you have ever seen the instructions for Rybelsus, they are unusually rigid: take it first thing in the morning on an empty stomach, with no more than about half a glass of water, and then wait at least 30 minutes before eating, drinking, or taking other medications. These are not arbitrary recommendations. They exist because oral semaglutide’s absorption is extremely sensitive to conditions in the stomach.
Pharmacokinetic analyses found that the bioavailability of oral semaglutide under recommended dosing conditions (30 minutes of post-dose fasting, no more than 120 mL of water) was about 0.8 percent. That means less than one percent of the semaglutide you swallow actually makes it into your blood. Extending the post-dose fasting time improved absorption, with bioavailability climbing to a plateau around 1.4 percent at 120 minutes of fasting. Drinking a larger volume of water (240 mL instead of 120 mL) reduced absorption.
8PubMed Central. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology TrialsFood had an even more dramatic effect. In a dedicated food-effect trial, subjects who took the tablet in a fed state had little to no measurable semaglutide in their blood, while all subjects who took it fasting had detectable levels.
9PubMed Central. Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet FormulationThis is worth emphasizing because it reframes what “oral peptide delivery” actually means in practice right now. The drug works clinically despite the tiny absorption fraction because the dose in the tablet is loaded high enough to compensate. But the margin for error is thin, and patient compliance with the dosing ritual matters a great deal for consistent drug levels.
Chemical Modifications That Toughen Peptides
Rather than relying entirely on delivery technology, another strategy is to redesign the peptide itself so it resists digestion. Two of the most studied modifications are backbone cyclization and N-methylation. Cyclization connects a peptide’s ends (or internal positions) into a ring, which shrinks its three-dimensional shape and hides vulnerable bonds from enzymes. In one study, backbone cyclization increased intestinal permeability roughly five-fold compared to linear versions of the same peptide, while also dramatically reducing breakdown by brush border enzymes.
10Journal of Medicinal Chemistry. Effect of Structural and Conformation Modifications, Including Backbone Cyclization, of Hydrophilic Hexapeptides on Their Intestinal Permeability and Enzymatic StabilityN-methylation adds a methyl group to the nitrogen in a peptide bond, which restricts how the molecule can flex and makes it harder for enzymes to grab. Research on melanocortin peptides found that combining backbone cyclization with N-methylation maintained enzyme resistance while improving selectivity for target receptors.
11PubMed Central. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptidesThese modifications do not automatically make a peptide orally bioavailable, but they chip away at the enzymatic barrier. The drug cyclosporine, a naturally cyclic peptide used as an immunosuppressant, is one of the oldest examples of an orally active peptide and owes its stability in large part to its cyclic, heavily N-methylated structure. More recently, researchers have been systematically applying N-methylation to cyclic peptide candidates to optimize their oral bioavailability.
12PubMed. Improving oral bioavailability of cyclic peptides by N-methylationLipid-Based Delivery Systems
Another approach wraps peptides in tiny fat droplets. Self-emulsifying drug delivery systems (SEDDS) are liquid or semi-solid formulations that spontaneously form nanoscale emulsions when they hit the watery environment of the gut. The lipid coating can shield the peptide from enzymes, help it penetrate the mucus layer that lines the intestine, and promote contact with the absorptive surface.
13PubMed. Self-emulsifying drug delivery systems in oral (poly)peptide drug deliveryIn one animal study, the diabetes drug exenatide was paired with a bile salt to make it more fat-soluble, then loaded into a SEDDS formulation. The resulting nano-droplets (about 46 nm across) diffused through mucus about 2.7 times better than exenatide in plain solution. When given orally to rats, the formulation achieved a relative bioavailability of roughly 15 percent compared to injection, and significantly lowered blood glucose.
14PubMed. In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatideFifteen percent bioavailability would be a remarkable number for an oral peptide in humans, though translating rat results to people is always uncertain. Still, SEDDS formulations are attractive because they can be manufactured simply and filled into standard capsules, making them practical for commercial scale.
Ingestible Devices That Bypass the Gut Barrier Entirely
Some of the most creative recent work sidesteps the absorption problem altogether by delivering peptides directly through the gut wall using ingestible microneedle devices. These are swallowable capsules that, once they reach the stomach or intestine, deploy tiny drug-loaded needles into the tissue lining. Because the needles deliver the drug beneath the epithelial barrier, they skip the enzymatic gauntlet and the permeability problem in one step.
One such device, inspired by the defensive inflation of a porcupinefish, is a capsule that swells by absorbing intestinal fluid and uses the gut’s own squeezing contractions to press barbed microneedles into the intestinal wall. In minipig experiments, this device achieved insulin bioavailability of about 24 percent, well above the roughly 10 percent that other robotic pill designs for insulin had managed.
15PubMed Central. Pain-free oral delivery of biologic drugs using intestinal peristalsis–actuated microneedle robotsAnother team developed a capsule with a magnetically controlled cantilever arm that, when triggered by a handheld magnet outside the body, deploys drug-loaded microneedles to a targeted location in the intestinal tract in under three seconds.
16Device. Magnetically controlled cantilever actuator capsule for localized mucosal drug delivery in the gastrointestinal tractThese devices are still experimental and raise practical questions about manufacturing cost, patient comfort, and whether tiny needles repeatedly puncturing the gut wall could cause problems over months of daily use. But the bioavailability numbers they are producing in animals are far higher than anything chemical formulations have achieved for large peptides like insulin, which makes them a genuinely promising long-term bet.
The Oral Insulin Challenge
Oral insulin has been a goal of drug delivery research for decades, and it remains one of the hardest problems in the field. Insulin is structurally vulnerable in ways that go beyond typical peptide fragility: its disulfide bonds can be cleaved by gastric acid, causing the molecule to unfold and become inactive even before enzymes get to it. In the intestine, trypsin and chymotrypsin degrade it further.
17PubMed Central. Recent Advances in Oral Insulin Delivery TechnologiesResearchers have tried enzyme inhibitors like aprotinin and camostat, encapsulation strategies to shield insulin from acid, and permeation enhancers that temporarily open tight junctions. The tight-junction approach carries safety concerns: holding those junctions open for too long could let bacteria, toxins, and other unwanted molecules cross the gut barrier, potentially increasing the risk of infection or inflammatory disease.
17PubMed Central. Recent Advances in Oral Insulin Delivery TechnologiesCell-penetrating peptides offer another angle. These short peptide sequences can cross cell membranes and carry cargo molecules with them. Combined with nanoparticles for added stability, cell-penetrating peptides may improve epithelial permeability enough to make oral insulin viable, though this work is still largely preclinical.
18PubMed Central. Nanoparticles with Cell-Penetrating Peptides for Oral Delivery: A Case for Oral Delivery of InsulinNo oral insulin product has reached the market yet. The gap between a promising rat study and a reliable human pill is vast, in part because insulin dosing has to be precise. Too much insulin causes dangerous drops in blood sugar; too little does nothing. The high variability of gut absorption makes that precision very hard to achieve orally.
What About Collagen and Supplement Peptides?
Collagen peptide supplements are the most widely consumed oral peptide products, and they operate by a fundamentally different logic than peptide drugs. Collagen hydrolysates are pre-digested: the collagen protein is already broken down into short fragments before you swallow them. Many of these fragments are small enough (di- and tripeptides) to be absorbed through the PepT1 transporter described earlier.
A randomized crossover study in healthy people confirmed that after ingesting collagen hydrolysate, both free hydroxyproline and hydroxyproline-containing di- and tripeptides appeared in the blood, indicating that a meaningful fraction survived digestion and was absorbed intact.
19PubMed Central. Absorption of bioactive peptides following collagen hydrolysate intake: a randomized, double-blind crossover study in healthy individualsOne particularly stable tripeptide, Gly-3Hyp-4Hyp, was found in human blood at high concentrations after porcine collagen ingestion. It maintained its peak blood level for four hours, thanks to unusual resistance to blood enzymes.
20PubMed Central. Identification of a highly stable bioactive 3-hydroxyproline-containing tripeptide in human blood after collagen hydrolysate ingestionSo collagen peptides genuinely are absorbed orally. Whether those absorbed fragments then do anything meaningful at target tissues like skin or joints is a separate and more contentious question. But from a pure absorption standpoint, collagen supplements benefit from being small, pre-digested, and in the sweet spot for PepT1 transport. They do not face the same barriers as a large intact peptide drug that needs to arrive at its receptor without a single bond broken.
New Formulation Frontiers
Beyond the technologies already in clinical use or late-stage testing, a few newer approaches are worth watching. One team recently engineered a synthetic protein coating that self-assembles around peptide drugs and acts like an enteric shield. The coating hardens at stomach pH and dissolves when it reaches the higher pH of the intestine, protecting the cargo during the most destructive phase of digestion and releasing it where absorption is more feasible. The coating’s phase transitions are temperature- and pH-controlled, and both are reversible and tuned to match conditions in the gut.
21PubMed Central. Intrinsically Disordered Protein Coating for Oral Delivery of Peptide DrugsManufacturing remains a real bottleneck for the whole field. Many therapeutic peptides have complex structures that are expensive to synthesize chemically at large scale. Lanthipeptides, for example, are a class of peptides with promising biological activity but elaborate architectures that make chemical synthesis economically impractical for mass production. Biological production methods (growing the peptides in engineered microbes) may be the only realistic alternative for some candidates.
22PubMed Central. Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical productionEven when formulation science solves the absorption problem, the cost of producing the peptide itself and loading it into a specialized delivery system at commercial scale will determine whether an oral peptide product is viable. With oral semaglutide, the tablet contains far more drug than the body actually absorbs, which means manufacturing costs are directly inflated by the low bioavailability. Any future technology that pushes absorption efficiency higher would not just improve clinical outcomes but also reduce the economic overhead of making oral peptide drugs accessible.